Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 10/20 | 0.80 |
| ▸ | STAT1 | P42224 | 1/20 | 0.80 |
| ▸ | STAT4 | Q14765 | 1/20 | 0.80 |
| ▸ | STAT5A | P42229 | 2/20 | 0.51 |
| ▸ | STAT5B | P51692 | 2/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.50 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 5/20 | 0.36 |
| ▸ | BIRC3 | Q13489 | 5/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 5/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22468634 | 0.97 | STAT3 (0.85) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL22468630 | 0.97 | STAT3 (0.85) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL30308660 | 0.96 | STAT3 (0.80) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL30308589 | 0.96 | STAT3 (0.73) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL25214303 | 0.94 | STAT3 (0.83) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL30308547 | 0.94 | STAT3 (0.83) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL25214297 | 0.94 | STAT3 (0.83) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL25265783 | 0.93 | STAT3 (0.78) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL25265784 | 0.93 | STAT3 (0.78) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL25211359 | 0.93 | STAT3 (0.77) | STAT3STAT1STAT4STAT5ASTAT5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-04 | — | — | US | disclosed |
| US-20230083015-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | UNIV MICHIGAN REGENTS (US) | 2023-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230083015-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | STAT1, STAT3, JAK2 | STAT3 2/4885STAT1 1/4885STAT4 6/4885 |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | HLA-DRB1, CD74, HLA-C | STAT3 2125/4885STAT1 893/4885STAT4 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.